Alteration of various metabolites has been linked to type 2 diabetes (T2D) and insulin resistance. New insights in the field is presented in the article Integration of whole-body [18F]FDG PET/MRI with non-targeted metabolomics can provide new insights on tissue-specific insulin resistance in type 2 diabetes. A team from Uppsala university in collaboration with AstraZeneca presented novel associations between several metabolites from subcutaneous adipose tissue (SAT) and plasma with the fat fraction, volume and insulin sensitivity of various tissues throughout the body. The new approach used is an integrative multi-omics approach, including data from both Antaros’ proprietary method Imiomics (based on imaging studies) and metabolomics.
Stanko Skrtic, Dept of Medicine, Sahlgrenska University hospital and AstraZeneca AB comments: “What we know, this is the first attempt to explore diabetes type 2 by integrating whole-body imaging data and metabolomics.”
The team performed cross-sectional metabolic profiling for SAT and plasma in a cohort of 42 subjects (incl healthy, pre-diabetic and T2D subjects) that underwent glucose tolerance test (OGTT) and whole-body PET/MRI during hyperinsulinemic euglycemic clamp. This unique imaging approach achieves what can be described as whole-body imaging in insulin resistance.
The presented multi-omics approach can be used to generate hypotheses for the pathobiology of T2D development, including different disease stages and patient phenotypes.